Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)
Study sponsor: Dyne Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2030-12Estimated
Enrollment · participants90Estimated
Source updated2026-05-27Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.